Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SLGL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| S6G5T-8 | Acne Vulgaris | Phase 3 · NCT03761810 | Completed |
| Patidegib Topical Gel | Gorlin Syndrome | Phase 3 · NCT06050122 | Completed |
| Patidegib Topical Gel, 2% | Basal Cell Nevus Syndrome | Phase 3 · NCT04308395 | Terminated |
| 5-FU Cream | Actinic Keratosis (AK) | Phase 3 · NCT03727074 | Completed |
| S6G5T-3 | Acne Vulgaris | Phase 3 · NCT03761810 | Completed |
| S5G4T-1 | Papulopustular Rosacea | Phase 3 · NCT03564145 | Terminated |
| S5G4T-2 | Papulopustular Rosacea | Phase 3 · NCT03564119 | Completed |
| S2G6T-3 | Tinea Pedis | Phase 2 · NCT02842021 | Terminated |
| S6G5T-7 | Acne Vulgaris | Phase 2 · NCT02661958 | Completed |
| S6G5T-6 | Acne Vulgaris | Phase 2 · NCT02661958 | Completed |
| S6G5T-5 | Acne Vulgaris | Phase 2 · NCT02661958 | Completed |
| S6G5T-1 | Acne Vulgaris | Phase 2 · NCT02661958 | Completed |
| S2G6T-4 | Tinea Pedis | Phase 2 · NCT02842021 | Terminated |
| S2G6T-2 | Tinea Pedis | Phase 2 · NCT02842021 | Terminated |
| S2G6T-1 | Tinea Pedis | Phase 2 · NCT02842021 | Terminated |
| DER 45 EV | Rosacea | Phase 2 · NCT00940992 | Completed |
Also used in these trials (approved or third-party drugs, not SLGL's own candidates): Fluorouracil.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SLGL holds $47.9M in cash and short-term investments and burns about $2.1M/quarter from operations, an estimated runway of 67.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SLGL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Moshe Arkin Chairman of Board and CEO, Director, 10% |
Insider | 1,950,113 | 69.99% | 2026-03-25 |
| Opaleye Management Inc. 10% owner |
Insider | 540,000 | 19.38% | 2026-09-30 |
| Great Point Partners, LLC | Institution (13G, 5%+) | 274,363 | 9.85% | 2026-03-24 |
| Trails Edge Capital Partners, LP | Institution (13G, 5%+) | 166,473 | 5.98% | 2026-10-20 |
| Ran Gottfried Director |
Insider | 1,550 | 0.06% | 2026-03-18 |
| Michael Glezin Chief Business Officer |
Insider | 1,500 | 0.05% | 2026-03-18 |
| Ofer Toledano VP Research & Dev. |
Insider | 1,461 | 0.05% | 2026-03-18 |
| Eyal Ben-Or Chief Financial Officer |
Insider | 1,000 | 0.04% | 2026-03-18 |
Share count 2,786,158 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SLGL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →